Safety and Effectiveness of Antegrade Flexible Ureteroscopy-Assisted Percutaneous Nephrolithotomy for Staghorn Calculi

Background Renal calculi are among the most common diseases in urology. Current treatment options include extracorporeal shock wave lithotripsy (ESWL), flexible ureteroscopic lithotripsy, and percutaneous nephrolithotomy (PCNL). For renal stones ≥2 cm, PCNL is the recommended first-line treatment.

However, because of the large stone burden and the involvement of multiple calyces, it is often difficult to achieve complete clearance with a single PCNL session. Excessive angulation of the nephroscope may increase the risk of infundibular tears and bleeding, and stones located in parallel or narrow infundibula may be difficult to access, reducing the one-stage stone-free rate. To improve outcomes, several strategies have been adopted:

Multiple percutaneous tracts: Establishing additional tracts allows access to calyces unreachable from the primary tract and increases stone-free rates. However, this also increases the risks of bleeding, infection, and injury to the kidney or adjacent organs. In addition, expansion of the first tract may cause perirenal hematoma or morphological changes due to urine extravasation, making subsequent punctures more challenging. Multiple tracts also prolong postoperative recovery and increase hospitalization costs. Staged procedures: The first PCNL session removes stones in the renal pelvis and accessible calyces, while residual stones are addressed in a second-stage retrograde ureteroscopy. This reduces the risks compared with multiple tracts, but prolongs the treatment cycle and increases costs. Endoscopic combined intrarenal surgery (ECIRS) with modified patient positions: Positions such as the modified supine split-leg, lateral decubitus, or female-specific "Galdakao-modified supine Valdivia" allow simultaneous use of ureteroscopic and percutaneous approaches. This combines the efficiency of PCNL with the wide access angle of ureteroscopy, reduces the need for repositioning under anesthesia, and facilitates intraoperative monitoring. However, it requires two surgical teams, duplicate equipment, and high coordination, which may prolong operative time.

Previous studies suggest that combining single-tract PCNL with flexible ureteroscopy and holmium laser lithotripsy may be an ideal approach for staghorn stones. While antegrade cystoscopic lithotripsy accommodates thicker fibers and offers faster irrigation and clearer visualization, the larger diameter of the cystoscope limits its passage through the ureter, risking residual fragments. Recently, antegrade flexible ureteroscopy-assisted PCNL has been attempted, but most studies are small retrospective series or case reports. The limited adoption may be due to the high purchase and repair costs of reusable flexible ureteroscopes. The development of single-use ureteroscopes has largely overcome these barriers, providing a foundation for multicenter prospective studies.

Based on this background, a multicenter clinical study of antegrade flexible ureteroscopy-assisted PCNL for staghorn calculi has important clinical value. Our preliminary work showed that when the number of stone branches was ≥5, the need for multiple tracts and staged procedures increased, while operative time was prolonged, hospital stay was longer, and the stone-free rate was reduced. We therefore further compared the efficacy of standard PCNL and antegrade flexible ureteroscopy-assisted PCNL stratified by stone branch number.

Objective To evaluate the safety and efficacy of antegrade flexible ureteroscopy-assisted PCNL in the treatment of staghorn calculi, compared with standard PCNL.

Study Overview Design This is a prospective, multicenter clinical study. Population

Inclusion criteria

Diagnosis of staghorn calculi confirmed by non-contrast CT. Age ≥18 years. General condition suitable for surgery. Ability to understand and voluntarily sign informed consent.

Exclusion criteria

Solitary kidney or congenital anomalies (e.g., horseshoe kidney, ectopic kidney). Severe preoperative pyelonephritis. Psychiatric illness or lack of cooperation. Uncontrolled comorbidities (e.g., diabetes, hypertension) contraindicating surgery. Coagulation disorders. Investigator's judgment of unsuitability.

Withdrawal criteria:

Subject withdrawal: refusal to continue or loss to follow-up. Investigator withdrawal: complications making continuation unsafe, or poor compliance.

Sample size and grouping

A total of 420 patients will be enrolled across 14 centers (30 per center). Patients will be randomized into two groups:

Experimental group: antegrade flexible ureteroscopy-assisted PCNL (n=210). Control group: standard PCNL (n=210).

Procedures All patients will undergo preoperative urine culture. Infected patients will receive targeted antibiotics until negative. Surgery will be performed under general anesthesia with tracheal intubation.

Standard PCNL group: Residual stones inaccessible through the primary tract will be managed by establishing a second or third tract.

Antegrade flexible ureteroscopy-assisted PCNL group: Residual stones will first be managed using a flexible ureteroscope introduced via the established tract. The Tianjin Institute of Urology (TJIU) technique will be adopted, systematically inspecting all calyces and the ureter. Additional tracts will be created only if necessary.

At the end of surgery, a double-J stent and nephrostomy tube will be placed. Postoperative evaluation： Stone-free rate (no residual fragments ≥2 mm on CT on postoperative day 2). Operative time (from tract establishment to nephrostomy placement). Complications (Clavien-Dindo classification). Secondary procedures. Postoperative fever. Length of hospital stay. Subgroup analysis will be conducted based on the number of stone branches (≥5 vs <5).

Endpoints Primary endpoint: Stone-free rate. Secondary endpoints: surgeon-perceived smoothness of operation, treatment satisfaction, rate of secondary procedures, operative time, number of tracts, hemoglobin decrease, length of hospital stay, postoperative complications.

Adverse Events

Definitions:

Adverse event (AE): any unfavorable medical occurrence after treatment, not necessarily causally related.

Serious adverse event (SAE): hospitalization, prolonged hospitalization, disability, life-threatening condition, death, or congenital anomaly.

Severity:

Mild: tolerable, no specific treatment needed. Moderate: requires intervention, directly affects recovery. Severe: life-threatening, fatal, or disabling, requiring emergency treatment.

Reporting:

All AEs/SAEs will be documented in case report forms with onset, presentation, management, and outcome. SAEs will be reported within 24 hours to the sponsor, ethics committee, and regulatory authorities.

Statistical Analysis This randomized, open-label, multicenter trial uses stone-free rate (CT on day 2, no fragments ≥2 mm) as the primary outcome. Based on preliminary data (stone-free rate ~52% for PCNL and ~71% for antegrade flexible ureteroscopy-assisted PCNL), sample size was calculated with 90% power and α=0.025, requiring 157 patients per group. Allowing for 20% attrition, 210 patients per group (420 total) will be enrolled.

Data will be analyzed using R software (version 4.1.2). Continuous variables will be expressed as mean ± SD, categorical variables as frequencies and percentages. Student's t-test, chi-square test, or Fisher's exact test will be used as appropriate. Two-sided p-values <0.05 will be considered statistically significant.

Inclusion criteria

Staghorn calculi confirmed by non-contrast CT of the urinary system; Age ≥18 years; General condition suitable for surgical treatment; Ability to understand and voluntarily sign the informed consent form.

Exclusion criteria

Solitary kidney or congenital anomalies (such as horseshoe kidney or ectopic kidney); Patients with severe preoperative pyelonephritis; Patients with psychiatric disorders or unwilling to cooperate; Patients with uncontrolled diabetes or hypertension who cannot tolerate surgery; Patients with coagulation disorders; Patients deemed unsuitable for participation in this trial by the investigator.